Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CXCR4 | P61073 | 6/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4570867 | 1.00 | LMNA (0.46) | LMNAALDH1A1MAPTKDM4EMEN1 | |
| SCHEMBL23374594 | 1.00 | LMNA (0.46) | LMNAALDH1A1MAPTKDM4EMEN1 | |
| SCHEMBL16438632 | 0.93 | LMNA (0.44) | LMNAMAPT | |
| SCHEMBL18212487 | 0.93 | LMNA (0.44) | LMNAMAPT | |
| SCHEMBL14370057 | 0.93 | LMNA (0.44) | LMNAMAPT | |
| SCHEMBL20021298 | 0.84 | — | — | |
| SCHEMBL9801414 | 0.83 | LMNA (0.51) | LMNAALDH1A1MAPTKDM4EMEN1 | |
| SCHEMBL3661871 | 0.83 | ALDH1A1 (0.45) | LMNAALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL23183278 | 0.82 | LMNA (0.43) | LMNAALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL17828063 | 0.80 | LMNA (0.46) | LMNAALDH1A1MAPTKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | claimed |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | NOVARTIS AG (CH) | 2023-04-06 | — | — | US | claimed |
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | disclosed |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | NOVARTIS AG (CH) | 2023-04-06 | — | — | US | disclosed |
| US-11548870-B2 | Compounds useful as inhibitors of helios protein | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210147383-A1 | COMPOUNDS USEFUL AS INHIBITORS OF HELIOS PROTEIN | BRISTOL-MYERS SQUIBB COMPANY | 2021-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | LMNA 2327/4885ALDH1A1 1243/4885MAPT 4148/4885 |
| US-20210147383-A1 | COMPOUNDS USEFUL AS INHIBITORS OF HELIOS PROTEIN | IKZF2, RPL6, HNRNPR | LMNA 1301/4885ALDH1A1 3947/4885MAPT 3157/4885 |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | HBZ, ZFX, WIZ | LMNA 2327/4885ALDH1A1 1243/4885MAPT 4148/4885 |
| US-11548870-B2 | Compounds useful as inhibitors of helios protein | IKZF2, RPL6, HNRNPR | LMNA 1301/4885ALDH1A1 3947/4885MAPT 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.